Makers of smartwatches and other wearables have spent years trying to measure blood sugar without pricking your skin. The ...

The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

Acesion Pharma has begun enrolling patients into a phase 2 clinical trial of AP31969, its novel oral SK ion channel inhibitor being developed for rhythm control in atrial fibrillation.

AP31969 is a novel, first-in-class, oral SK ion channel inhibitor intended for rhythm control of atrial fibrillation and has recently completed Phase 1 in healthy volunteersPhase 2 trial will assess ...

After approval in late 2024, Johnson & Johnson's Varipulse PFA system started 2025 on the wrong foot: Its early rollout had ...

Developments shaping the medtech industry in 2025 offer a glimpse of what may unfold as we head into the new year.

Contemporary cardiology faces a paradox: unprecedented technological capability coincides with declining scientific curiosity ...

Apple Watch blood sugar monitoring is something the company reportedly wanted to do right from the start. A report ...

Luma Vision announced that it completed 15 AFib ablation procedures as part of a clinical study in collaboration with CardioFocus.

AliveCor’s latest attempt to revive its Apple Watch antitrust case fell short this week, with a federal appeals court ...

On Monday, the U.S. Food and Drug Administration (FDA) approved Abbott Laboratories’ (NYSE: ABT) Volt PFA System to treat patients battling atrial fibrillation (AFib). AFib is the most common type of ...

Wearable health devices such as smartwatches and bands are more than fitness trackers. Many also can monitor your cardiovascular health. Some wearables can highlight problems such as irregular heart ...